Consensus evidence supports this rationale because high T-cell infiltration in the tumor microenvironment often correlates with clinical response to approved anti Programmed cell death protein 1 (αPD1) and anti Programmed death-ligand 1 (αPDL1) blocking antibodies (4, 5). The gene discussed is PDCD1; the disease is neoplasm.